Compared to Estimates, Amphastar (AMPH) Q4 Earnings: A Look at Key Metrics

Core Insights - Amphastar Pharmaceuticals reported a revenue of $183.11 million for the quarter ended December 2025, reflecting a year-over-year decline of 1.8% and an EPS of $0.73, down from $0.92 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $194.03 million by 5.63%, while the EPS was 24.49% below the consensus estimate of $0.97 [1] Revenue Performance - BAQSIMI generated net revenues of $46.71 million, which is 11.8% higher year-over-year but below the average estimate of $52.07 million from two analysts [4] - Primatene MIST reported net revenues of $27.93 million, a decrease of 3.5% compared to the previous year and below the estimated $31.48 million [4] - Lidocaine achieved net revenues of $14.9 million, exceeding the estimate of $13.51 million and showing a year-over-year increase of 3.5% [4] - Epinephrine's net revenues were $17.09 million, down 8.6% year-over-year and below the average estimate of $19.78 million [4] - Glucagon reported net revenues of $14.08 million, significantly higher than the estimated $10.59 million, but this represents a drastic year-over-year decline of 45% [4] Stock Performance - Amphastar's shares have returned +7.1% over the past month, outperforming the Zacks S&P 500 composite, which saw a change of +0.6% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]